Reprint

Hurdles for Phage Therapy (PT) to Become a Reality

Edited by
August 2019
484 pages
  • ISBN978-3-03921-391-7 (Paperback)
  • ISBN978-3-03921-392-4 (PDF)

This is a Reprint of the Special Issue Hurdles for Phage Therapy (PT) to Become a Reality that was published in

Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare
Summary

Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant bacterial cells, they could represent ideal antimicrobials for fighting the antibiotic resistance crisis. The medical use of bacteriophages has become known as phage therapy. It is widely used in Russia, where phage cocktails are sold in pharmacies as an over-the-counter drug. However, no phage product has been registered for medical purposes outside of the former Soviet Union. The current Special Issue of Viruses contains a collection of papers from opinion leaders in the field who explore hurdles to the introduction of phage therapy in western countries. The articles cover diverse topics ranging from patent to regulatory issues, the targeting of suitable bacterial infections, and the selection and characterization of safe and efficient phage cocktails. Phage resistance is discussed, and gaps in our knowledge of phage–bacterium interactions in the mammalian body are revealed, while other articles explore the use of phages in food production and processing.

Format
  • Paperback
License and Copyright
© 2019 by the authors; CC BY-NC-ND license
Keywords
Staphylococcus aureus; bacteriophage; phage therapy; vB_SauM-fRuSau02; Twortlikevirus; antibiotic; antimicrobial resistance; magistral preparation; compounding pharmacy; phage therapy; regulatory framework; personalized medicine; bacteriophage; phage; horizontal gene transfer; co-evolution; phage therapy; industrial phage application; antimicrobial resistance (AMR); Germany; pH stability; phage-host interactions; genomics; antibiotic-resistance; phage preparation; lysins; biofilms; typhoid fever; Salmonella Typhi; extended-spectrum beta lactamases (ESBL); Democratic Republic of the Congo; bacteriophages; MALDI-MS; Staphylococcus; bacteriophages; phage therapy; Kayvirus; Viral proteins; bacteriophage; therapy; phage therapy; bacterial disease; infection; target selection; Bacteriophage; phage therapy; resistance; adaptation; prophage; production; regulation; phage therapy; viral genomes; best practices; IND; high-throughput sequencing; bacteriophages; phages; food safety; foodborne illness; phage therapy; history of science; science communication; bacteriophage; phage therapy; sustainable agriculture; zoonosis; antibiotic resistance; phage therapy; experimental therapy; phage cocktails; anti-phage antibodies; prophage; immunomodulation; phage therapy; evolution; bacterial resistance; virulence; Listeria ivanovii; bacteriophages; alginate; production; disinfection; phagodisinfection; virus–host interactions; bacteriophage efficacy; gastrointestinal tract; phage therapy; bacteriophage; phage therapy; antimicrobial resistance; antibiotic; global health; developing countries; infectious disease; bacteriophage; phage; phage therapy; phage-resistance; phage therapy; bacterial infection; capsule depolymerase; antibiotic; animal model; bacterial resistance; bacteriophage; immunology; innate immunity; adaptive immunity; human host; phage-human host interaction; bacterial infection; antibiotic resistance; bacteriophage; antibiotic therapy; phage therapy; cases report; abortive infection; prophage; adsorption; Enterococcus; rhamnopolysaccharide; bacteriophage; phage therapy; Staphylococcus aureus; biofilm; antimicrobial; frequency of resistance; phage sensitivity; resistance management; nontraditional antibacterial; bacteriophages; phage therapy; antibiotic resistance; Pseudomonas aeruginosa; Escherichia coli; Staphylococcus aureus; Brussels; Belgium; phage biocontrol; patent landscape; crop production; bacteriophage; phage therapy; multidrug-resistant bacteria; antimicrobial resistance; bacteriophage therapy; compassionate use; antibiotic resistance; phage therapy; PTMP; ATMP; regulatory framework; pharmaceutical paradigm shift; clinical trial; magistral formula; personalized medicine; phage therapy; E. faecalis; OrthoMCL; antimicrobial resistance; capsule; Galleria mellonella; Klebsiella pneumoniae; phage therapy; n/a; antimicrobial resistance; bacteriophage; personalised medicines; phage therapy; pharmaceutical legislation; regulatory framework

Related Books

November 2020

Bacteriophages

Biology & Life Sciences
...
September 2020

Feature Paper in Antibiotics for 2019

Medicine & Pharmacology